title: Author's reply: To PMID 24550591.
authors.affiliation: Department of Medical Statistics and Epidemiology, Hamad Medical Corporation and, Departments of Public Health and Medical Education, Weill Cornell Medical College, Doha, Qatar.
authors.forename: Abdulbari
authors.initials: A
authors.lastname: Bener
authors.affiliation: Department of Chemistry, Faculty of Arts and Science, Yildiz Technical University, Istanbul, Turkey.
authors.forename: Muzeyyen
authors.initials: M
authors.lastname: Dogan
authors.affiliation: Clinical Pharmacy, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
authors.forename: Lolwa
authors.initials: L
authors.lastname: Barakat
authors.affiliation: Diabetes and Health Education, Qatar Diabetic Association, and Qatar Foundation, Doha, Qatar.
authors.forename: Abdulla O A A
authors.initials: AO
authors.lastname: Al-Hamaq
mesh_terms: D003362:Cost-Benefit Analysis; D048909:Diabetes Complications / Q000188:drug therapy*; D050171:Dyslipidemias / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
references.citation: Indian J Pharmacol. 2014 Jan-Feb;46(1):88-93
references.pmid: 24550591